| Identification | Back Directory | [Name]
Carbamic acid, N-[2-[[[[(1S)-1-(chloromethyl)-2,3-dihydro-3-[[6-[[4-(methoxymethoxy)benzoyl]amino]imidazo[1,2-a]pyridin-2-yl]carbonyl]-9-methyl-1H-benz[e]indol-5-yl]oxy]carbonyl][2-(2-hydroxyethoxy)ethyl]amino]ethyl]-N-methyl-, 1,1-dimethylethyl ester | [CAS]
2222445-87-4 | [Synonyms]
Carbamic acid, N-[2-[[[[(1S)-1-(chloromethyl)-2,3-dihydro-3-[[6-[[4-(methoxymethoxy)benzoyl]amino]imidazo[1,2-a]pyridin-2-yl]carbonyl]-9-methyl-1H-benz[e]indol-5-yl]oxy]carbonyl][2-(2-hydroxyethoxy)ethyl]amino]ethyl]-N-methyl-, 1,1-dimethylethyl ester | [Molecular Formula]
C44H51ClN6O10 | [MOL File]
2222445-87-4.mol | [Molecular Weight]
859.36 |
| Hazard Information | Back Directory | [Uses]
MethylCBI-azaindole-benzamide-MOM-Boc-ethylenediamine-D is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. | [Biological Activity]
MethylCBI-azaindole-benzamide-MOM-Boc-ethylenediamine-D is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1]. | [IC 50]
Cleavable Linker | [References]
[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337. |
|
|